ĢAV

Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

ĢAV

Our Story
Learn more about our mission and how ĢAV came to be.
Learn More
Our Clients
Key decision-makers share why they find ĢAV so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about ĢAV.
Contact Us

Health

Some health systems expand local pharmacy services: But it’s not enough to fill gaps created by thousands of drugstore closings. We expect more consumers to explore alternative pharmacy offerings in 2025.

Households with GLP-1 users slash their spending on groceries: Food companies need to adapt to the shifting buying patterns of consumers on GLP-1s to stay competitive.

Over a quarter (27.9%) of US internet users use mobile apps to track their fitness and health, according to October 2024 data from Comscore.

US consumers see weight loss drugs as more effective than diet, exercise: Many plan to take a GLP-1 in 2025. Marketers in the health, wellness, and fitness spaces must pounce on the opportunity to frame their offerings as a better long-term bet than weight loss drugs.

Drugmakers plan price hikes on over 250 branded medications in US: Facing a hit under the Inflation Reduction Act, they’re taking matters into their own hands to offset lost revenue.

Consumers don’t want to pay for patient portal messages: And responding to messages takes up physicians’ ever-limited time. Here’s how AI chatbots could benefit both parties.

Keep it simple, smart, and familiar: Forget futuristic pendants and pins—AI wearables that look like regular gear but pack powerful features will be the ones capturing market share in 2025.

RFK Jr.’s pharmaceutical ad ban could affect $22 billion in ad spending: A business-friendly Trump administration could hamper RFK’s plans to cut D2C advertising.

Trump plans to “knock out” pharma’s middlemen: His comments sent shares of the three largest pharmacy benefit managers down in a sign of what’s to come under the incoming administration.

Health systems partner with wellness brands for digital advertising: We explore how legacy healthcare providers are offering health and wellness brands ad placements on their digital platforms to drive revenue and connect patients with medical products and services.

Dexcom launches genAI platform: Integrating its over-the-counter continuous glucose monitor with genAI is likely a test-case to work out any kinks before a wider rollout to those using its legacy products.

Patients have mixed opinions of healthcare tech: Healthcare organizations and marketers will need to keep innovating without compromising the patient experience.

The data: Nurses remain skeptical of the impact that AI will have in healthcare settings, according to Jarrard’s 2024 Nurse Survey Report. Some 837 US nurses were surveyed in September 2024.

Amazon’s biggest healthcare moves in 2024: Amazon has prioritized connecting Prime members with healthcare and pharmacy services. We examine which of its health-focused developments could be most impactful.

Consumers struggle to stick with healthy behaviors: There’s a disconnect between intent and behavior as consumers work to incorporate healthier habits into their daily routines. We discuss the opportunity for health marketers to close this gap.

CVS’ biggest healthcare moves in 2024: Eyeing a return to profitability for Aetna, the company prioritized cost-cutting measures and new leadership. We examine which of its health-focused moves could ultimately have the biggest impact on its bottom line.

Healthcare and pharma companies will lean further into D2C in 2025: They’re cutting out health insurers and PBMs that bottleneck patient access to their products and services. But the industry’s push into D2C won’t be met without challenges.

The battle between Big Pharma and D2C weight loss drug sellers will intensify in 2025: We explore the competitive GLP-1 drug market and detail what’s at stake for drugmakers and D2C companies selling compounded weight loss medications.

Digital health funding deal size steadied over the last two quarters: But with investors continuing to lean into a cautious spending approach, we expect startups’ funding woes to persist into 2025.

The high cost of healthcare will affect consumer behavior in 2025: Consumers are shopping around for health products and services, presenting companies with an opportunity to differentiate themselves by prioritizing customer service.